The renin angiotensin system is important in cardiovascular regulation and angiotensin II (ang II) is its primary mediator. Ang II activates receptors that are important in control of responsiveness but which have been studied largely indirectly, in contrast with many other receptors for which primary amino acid structure is known. The ang II receptor has been difficult to purify and clone. We now have isolated from a rat aortic cDNA library a clone that encodes a receptor with characteristics of the vascular smooth muscle ang II receptor. In COS cells transfected with this clone, [125I] Sar1-ile8-ang II binding is saturable with a Kd of 0.3 nM, and the receptor has an appropriate potency series for binding inhibition of ang II>ang III>ang I, with an IC50 for ang II of 1.6 nM. The nonpeptidic """"""""Type 1"""""""" ang II receptor antagonist DuP753 competes potently (IC50 6.2 nM), whereas the """"""""Type 2"""""""" antagonist PD123177 does not compete. These features of the transfected receptor are identical to those of the vascular receptor. We shall now exploit this advance to extend our previous work on the secondary signalling mechanisms of the ang II receptor in vascular smooth muscle to explore directly the structure-function relationships. Several areas will be investigated. First, we will examine how the ang II receptor relates to the superfamily of G-protein coupled receptors, since it is also coupled to phospholipase C through a G-protein. Second, we will attempt to account for the considerable heterogeneity of ang II-mediated pharmacological responses putatively attributed to the existence of more than one of the major observations of the current grant period - namely, that the vascular ang II receptor activates sequentially a phospholipase C and a phospholipase D, implying different phasic and tonic signalling mechanisms. This issue relates to the general question of how one receptor couples to different effector mechanisms. To achieve these goals we propose three Specific Aims: 1. To characterize rigorously the cDNA clone that we have isolated and to classify it structurally within the superfamily of G-protein coupled receptors; 2. To identify and characterize other ang II receptor subtypes; and 3. To define the structural determinants of ang II receptor coupling to different effector phospholipases. These data will provide important insights into molecular mechanisms of action of ang II and should have important implications for understanding the normal control of blood pressure and hypertension. In particular, it should now be possible to address the issue of whether the ang II receptor is a candidate gene contributing to hypertension.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL047557-03
Application #
2223758
Study Section
Pharmacology A Study Section (PHRA)
Project Start
1992-02-01
Project End
1996-01-31
Budget Start
1994-02-01
Budget End
1995-01-31
Support Year
3
Fiscal Year
1994
Total Cost
Indirect Cost
Name
Emory University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
042250712
City
Atlanta
State
GA
Country
United States
Zip Code
30322
Ushio-Fukai, M; Griendling, K K; Akers, M et al. (1998) Temporal dispersion of activation of phospholipase C-beta1 and -gamma isoforms by angiotensin II in vascular smooth muscle cells. Role of alphaq/11, alpha12, and beta gamma G protein subunits. J Biol Chem 273:19772-7
Kai, H; Alexander, R W; Ushio-Fukai, M et al. (1998) G-Protein binding domains of the angiotensin II AT1A receptors mapped with synthetic peptides selected from the receptor sequence. Biochem J 332 ( Pt 3):781-7
Griendling, K K; Ushio-Fukai, M; Lassegue, B et al. (1997) Angiotensin II signaling in vascular smooth muscle. New concepts. Hypertension 29:366-73
Ishizaka, N; Alexander, R W; Laursen, J B et al. (1997) G protein-coupled receptor kinase 5 in cultured vascular smooth muscle cells and rat aorta. Regulation by angiotensin II and hypertension. J Biol Chem 272:32482-8
Kai, H; Fukui, T; Lassegue, B et al. (1996) Prolonged exposure to agonist results in a reduction in the levels of the Gq/G11 alpha subunits in cultured vascular smooth muscle cells. Mol Pharmacol 49:96-104
Lassegue, B; Alexander, R W; Nickenig, G et al. (1995) Angiotensin II down-regulates the vascular smooth muscle AT1 receptor by transcriptional and post-transcriptional mechanisms: evidence for homologous and heterologous regulation. Mol Pharmacol 48:601-9
Kai, H; Griendling, K K; Lassegue, B et al. (1994) Agonist-induced phosphorylation of the vascular type 1 angiotensin II receptor. Hypertension 24:523-7
Takeuchi, K; Alexander, R W; Nakamura, Y et al. (1993) Molecular structure and transcriptional function of the rat vascular AT1a angiotensin receptor gene. Circ Res 73:612-21
Griendling, K K; Alexander, R W (1993) The angiotensin (AT1) receptor. Semin Nephrol 13:558-66
Murphy, T J; Nakamura, Y; Takeuchi, K et al. (1993) A cloned angiotensin receptor isoform from the turkey adrenal gland is pharmacologically distinct from mammalian angiotensin receptors. Mol Pharmacol 44:1-7

Showing the most recent 10 out of 14 publications